Pneumotox » Drug » Everolimus

Everolimus

5

Last update : 22/03/2016

I.a Pneumonitis (ILD), acute and/or severe (may cause ARDS)

2

I.b Pneumonitis (ILD)

4

I.d Organizing pneumonia pattern (an area or areas of consolidation on imaging)

1

I.f Acute fibrinous organizing pneumonia (AFOP)

1

I.h Subclinical pulmonary infiltrates/ILD

1

I.l Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

1

I.m ILD with a granulomatous component

2

I.p Fatal pneumonitis (ILD)

1

I.v Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence

2

I.y Progression, acceleration or exacerbation of preexisting ILD/fibrosis

1

I.ad Radiation recall pneumonitis

1

II.b ARDS - Acute lung injury

1

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

1

III.h Major/massive hemoptysis

1

IV.d Cough (lone)

1

V.h Chylothorax

1

V.i Pleuritis (can cause chest pain)

1

VI.a Pulmonary embolism - Venous thrombosis/thromboembolism

1

VIII.a Angioedema (may cause UAO, asphyxia and death)

2

XV.a Path: NSIP-cellular pattern (see also Ia, Ib)

1

XV.c Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

1

XV.d Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)

1

XV.e Path: ILD with a granulomatous component (see also Im)

1

XV.g Path: Alveolar hemorrhage (see also IIIa)

1

XVI.b Imaging: Ground-glass opacities (GGO) / shadowing

1

XVI.bl Imaging: An area or areas of avid tracer uptake in the lung/chest on 18F-PET scan

1

XVII.e Pneumocystis jiroveci pneumonia

1

Diagnosing DIRD

1

Drug and radiation history

2

Drug singularity - Correct identification of the drug

3

Consistent timing of exposure v. onset of symptoms

4

Clinical, imaging, BAL, pathological pattern consistent with the specific drug

5

Careful exlusion of another cause

6

Remission of symptoms with removal of drug

7

Recurrence with rechallenge (rarely advisable)

8

Causality assessment

More detailed checklist